Document:

Exhibit 10.1

 

AMPLIPHI BIOSCIENCES CORPORATION

 

CONSULTING AGREEMENT

 

This Consulting Agreement (this “Agreement”)
is entered into by and between AmpliPhi Biosciences Corporation, a Washington corporation (the “Company”),
and Wendy S. Johnson (“Consultant”), on September 3, 2015 (the “Execution Date”),
and shall be deemed to be effective as of July 1, 2015 (the “Effective Date”). The Company and Consultant previously
entered into that certain Interim Chief Operating Officer Agreement, dated September 18, 2014, as amended on January 15, 2015 (the
“Prior Consulting Agreement”), and desire for this Agreement to set forth the parties’ rights and obligations
with respect to Consultant’s provision of services to the Company as a consultant in lieu of the Prior Consulting Agreement,
effective on the Effective Date. In consideration of the mutual promises contained herein, the parties agree as follows:

 

1.           Services
and Compensation. Consultant agrees to perform for the Company the services described in Exhibit A (the “Services”),
and the Company agrees to pay Consultant the compensation described in Exhibit A for Consultant’s performance
of the Services.

 

2.           Confidentiality.

 

(a)           Definition.
“Confidential Information” means any and all information and materials, in whatever form, tangible or
intangible, whether disclosed to or learned or developed by Consultant before or after the execution of this Agreement, whether
or not marked or identified as confidential or proprietary, pertaining in any manner to the business of or used by the Company
and its affiliates, or pertaining in any manner to any person or entity to whom the Company owes a duty of confidentiality. Confidential
Information includes, but is not limited to, the following types of information and materials: (i) trade secrets, inventions, ideas,
processes, formulas, algorithms, pre-clinical and clinical data, formulations, programs, other works of authorship, know-how, improvements,
discoveries, developments, designs and techniques; (ii) information regarding plans for research, development, new products, marketing
and selling, business plans, business methods, budgets and unpublished financial statements, licenses, prices and costs, suppliers
and customers; (iii) sensitive personnel information including the skills and compensation of other employees of the Company; and
(iv) any other information or materials relating to the past, present, planned or foreseeable business, products, developments,
technology or activities of the Company. Consultant understands that Confidential Information includes, but is not limited to,
information pertaining to any aspect of the Company’s business which is either information not known by actual or potential
competitors of the Company or other third parties not under confidentiality obligations to the Company, or is otherwise proprietary
information of the Company or its customers or suppliers, whether of a technical nature or otherwise. Consultant further understands
that Confidential Information does not include any of the foregoing items which has become publicly and widely known and made generally
available through no wrongful act of Consultant or of others who were under confidentiality obligations as to the item or items
involved.

 

(b)           Nonuse
and Nondisclosure. Consultant will not, during or subsequent to the term of this Agreement, (i) use the Confidential Information
for any purpose whatsoever other than the performance of the Services on behalf of the Company or (ii) disclose the Confidential
Information to any third party except as reasonably required to perform the Services and under appropriate confidentiality agreements.
Consultant agrees that all Confidential Information will remain the sole property of the Company. Consultant also agrees to take
all reasonable precautions to prevent any unauthorized disclosure of such Confidential Information.

 

(c)           Former
Client Confidential Information. Consultant agrees that Consultant will not, during the term of this Agreement, improperly
use or disclose any proprietary information or trade secrets of any former or current employer of Consultant or other person or
entity with which Consultant has an agreement or duty to keep in confidence information acquired by Consultant, if any. Consultant
also agrees that Consultant will not bring onto the Company’s premises any unpublished document or proprietary information
belonging to any such employer, person or entity unless consented to in writing by such employer, person or entity.

 

    	 	1	 

     

    

 

(d)           Third
Party Confidential Information. Consultant recognizes that the Company has received and in the future will receive from third
parties their confidential or proprietary information subject to a duty on the Company’s part to maintain the confidentiality
of such information and to use it only for certain limited purposes. Consultant agrees that, during the term of this Agreement
and thereafter, Consultant owes the Company and such third parties a duty to hold all such confidential or proprietary information
in the strictest confidence and not to disclose it to any person, firm or corporation or to use it except as necessary in carrying
out the Services for the Company consistent with the Company’s agreement with such third party.

  

(e)           Return
of Materials. Upon the termination of this Agreement, or upon Company’s earlier request, Consultant will deliver to the
Company all of the Company’s property, including but not limited to all electronically stored information and passwords to
access such property, or Confidential Information that Consultant may have in Consultant’s possession or control.

 

3.           Ownership.

 

(a)           Assignment.
Consultant agrees that all inventions (whether or not patentable), copyrightable material, notes, records, drawings, designs, improvements,
developments, discoveries and trade secrets conceived, discovered, developed or reduced to practice by Consultant, solely or in
collaboration with others, during the term of this Agreement that relate in any manner to the business of the Company that Consultant
may be directed to undertake, investigate or experiment with or that Consultant may become associated with in work, investigation
or experimentation in the Company’s line of business in performing the Services under this Agreement (collectively, “Inventions”),
are the sole property of the Company. Consultant also agrees to assign (or cause to be assigned) and hereby assigns fully to
the Company all Inventions and any copyrights, patents, mask work rights or other intellectual property rights relating to all
Inventions.

 

(b)           Further
Assurances. Consultant agrees to assist Company, or its designee, at the Company’s expense, in every proper way to secure
the Company’s rights in Inventions and any copyrights, patents, mask work rights or other intellectual property rights relating
to all Inventions in any and all countries, including the disclosure to the Company of all pertinent information and data with
respect to all Inventions, the execution of all applications, specifications, oaths, assignments and all other instruments that
the Company may deem necessary in order to apply for and obtain such rights and in order to assign and convey to the Company, its
successors, assigns and nominees the sole and exclusive right, title and interest in and to all Inventions, and any copyrights,
patents, mask work rights or other intellectual property rights relating to all Inventions. Consultant also agrees that Consultant’s
obligation to execute or cause to be executed any such instrument or papers shall continue after the termination of this Agreement.

 

(c)           Pre-Existing
Materials. Attached as Exhibit B is a list describing with particularity all inventions, improvements, developments,
concepts, discoveries or other proprietary information which were (i) made by Consultant prior to becoming a consultant to the
Company and (ii) could reasonably be deemed to be in or related to the business of the Company (collectively referred to as “Prior
Inventions”), which belong solely to Consultant or belong to Consultant jointly with another, which relate in
any way to any of the Company’s proposed businesses, products or research and development, and which are not assigned to
the Company hereunder; or, if no such list is attached, Consultant represents that there are no such Prior Inventions. Subject
to Section 3(a), Consultant agrees that if, in the course of performing the Services, Consultant incorporates into any Invention
developed under this Agreement any Prior Invention owned by Consultant or in which Consultant has an interest, (i) Consultant will
inform Company, in writing before incorporating such Prior Invention into any Invention, and (ii) the Company is hereby granted
a nonexclusive, royalty-free, perpetual, irrevocable, worldwide license to make, have made, modify, use and sell such Prior Invention
as part of or in connection with such Invention. Consultant will not incorporate any invention, improvement, development, concept,
discovery or other proprietary information owned by any third party into any Invention without Company’s prior written permission.

 

(d)           Attorney-in-Fact.
Consultant agrees that, if the Company is unable because of Consultant’s unavailability, dissolution, mental or physical
incapacity, or for any other reason, to secure Consultant’s signature for the purpose of applying for or pursuing any application
for any United States or foreign patents or mask work or copyright registrations covering the Inventions assigned to the Company
in Section 3(a), then Consultant hereby irrevocably designates and appoints the Company and its duly authorized officers and agents
as Consultant’s agent and attorney-in-fact, to act for and on Consultant’s behalf to execute and file any such applications
and to do all other lawfully permitted acts to further the prosecution and issuance of patents, copyright and mask work registrations
with the same legal force and effect as if executed by Consultant.

  

 

    	 	2	 

     

    

 

4.           Conflicting
Obligations. Consultant certifies that Consultant has no outstanding agreement or obligation that is in conflict with any of
the provisions of this Agreement or that would preclude Consultant from complying with the provisions of this Agreement. Consultant
will not enter into any such conflicting agreement during the term of this Agreement. Consultant’s violation of this Section
4 will be considered a breach of a material provision of this Agreement under Section 6(b)(i)(1).

 

5.           Reports.
Consultant also agrees that Consultant will, from time to time during the term of this Agreement or any extension thereof, keep
the Company advised as to Consultant’s progress in performing the Services under this Agreement. Consultant further agrees
that Consultant will, as requested by the Company, prepare written reports with respect to such progress.

 

6.           Term
and Termination.

 

(a)         Term.
This Agreement is effective as of the Effective Date and will terminate on the earlier of (i) July 1, 2016 or (ii) termination
as provided in Section 6(b) below. The term of this Agreement may be extended upon mutual written agreement of the parties.

 

(b)       Termination.

 

		(i)	Termination by the Company.

 

(1) For Cause. The Company
may terminate this Agreement immediately and without prior notice if Consultant refuses to or is unable to perform the Services
or is in breach of any material provision of this Agreement. Such right to terminate this Agreement for cause shall be in addition
to any other remedies available to the Company at law or in equity.

 

(2) Without Cause. The Company
may terminate this Agreement for any reason, or no reason, upon at least 90 days’ prior written notice to Consultant; provided,
however, in no event may the effective date of any termination pursuant to this Section 6(b)(i)(2) occur before March 31, 2016.
 

 

		(ii)	Termination by Consultant.

 

(1) For Cause. Consultant
may terminate this Agreement upon written notice to the Company if the Company is in breach of any material provision of this Agreement
and does not cure the breach within thirty (30) days following receipt of written notice thereof from Consultant. Such right to
terminate this Agreement for cause shall be in addition to any other remedies available to Consultant at law or in equity.

 

(2) Without Cause. Consultant
may terminate this Agreement for any reason, or no reason, upon at least 45 days’ prior written notice to the Company.

 

(c)         Survival.
Upon such termination, all rights and duties of the Company and Consultant toward each other shall cease except:

 

(i)           The
Company will pay, within 30 days after the effective date of termination, all amounts owing to Consultant for Services completed
and accepted by the Company prior to the termination date and related expenses, if any, submitted in accordance with the Company’s
policies and in accordance with the provisions of Section 1 of this Agreement; and

 

(ii)           Section
2 (Confidentiality), Section 3 (Ownership), Section 6 (Term and Termination—Survival), Section 7 (Independent Contractor;
Benefits) and Section 9 (Miscellaneous) will survive termination of this Agreement.

 

    	 	3	 

     

    

 

7.           Independent
Contractor; Benefits.

 

(a)         Independent
Contractor. It is the express intention of the Company and Consultant that Consultant perform the Services as an independent
contractor to the Company. Nothing in this Agreement shall in any way be construed to constitute Consultant as an employee of the
Company. Consultant agrees to furnish (or reimburse the Company for) all tools and materials necessary to accomplish this Agreement
and shall incur all expenses associated with performance, except as expressly provided in Exhibit A. Consultant acknowledges
and agrees that Consultant is obligated to report as income all compensation received by Consultant pursuant to this Agreement.
Consultant agrees to and acknowledges the obligation to pay all self-employment and other taxes on such income.

 

(b)         Benefits.
The Company and Consultant agree that Consultant will receive no Company-sponsored benefits from the Company. If Consultant is
reclassified by a state or federal agency or court as Company’s employee, Consultant will become a reclassified employee
and will receive no benefits from the Company, except those mandated by state or federal law, even if by the terms of the Company’s
benefit plans or programs of the Company in effect at the time of such reclassification, Consultant would otherwise be eligible
for such benefits.

 

8.           Indemnification
Agreement. The Company and Consultant acknowledge that the Company and Consultant have entered into that certain Indemnification
Agreement, dated June 1, 2014 (the “Indemnification Agreement”), and that nothing herein is intended to limit
or modify the parties’ rights or obligations under the Indemnification Agreement.

  

9.           Miscellaneous.

 

(a)           Governing
Law. This Agreement shall be governed by the laws of the Commonwealth of Virginia without regard to conflicts of law rules.

 

(b)           Assignability.
Consultant may not sell, assign or delegate any rights or obligations under this Agreement without the express prior written consent
of the Company. The Company may assign (i) this Agreement to a Company affiliate or (ii) this Agreement in the event of a merger,
acquisition or sale of all or substantially all of the assets of the Company. Subject to the foregoing, this Agreement will be
binding upon and inure to the benefit of the parties hereto, their successors and assigns. Any attempted assignment in violation
of this provision will be null and void.

 

(c)           Entire
Agreement. This Agreement and the Indemnification Agreement constitute the entire agreement between the parties with respect
to the subject matter hereof and thereof and supersede all prior written and oral agreements between the parties regarding the
subject matter hereof and thereof. The Company and Consultant hereby agree that the Prior
Consulting Agreement shall be deemed to have been in continuous effect from the effective date thereof to the Effective Date. Effective
on the Effective Date, the Prior Consulting Agreement is hereby terminated and of no further force or effect; provided, however,
nothing in the foregoing will relieve either party of any obligations accrued under the Prior Consulting Agreement prior to the
Effective Date, nor will it affect the survival of any provision intended to survive the termination of the Prior Consulting Agreement.

 

(d)           Headings.
Headings are used in this Agreement for reference only and shall not be considered when interpreting this Agreement.

 

(e)           Notices.
Any notice or other communication required or permitted by this Agreement must be in writing and must be (i) mailed by nationally
recognized overnight courier, with written verification of delivery, (ii) sent by email or facsimile, or (iii) delivered by hand
to the party to whom such notice is required or permitted to be given. If mailed by overnight courier, any such communication will
be considered to have been given one (1) business day after it was mailed, as evidenced by written verification from such courier.
If delivered by email or facsimile, any such communication will be considered to have been given on the day of its transmission
if sent during normal business hours of the recipient, and if not during normal business hours of the recipient, then on the next
business day. If delivered by hand, any such communication will be considered to have been given when received by the party to
whom notice is given, as evidenced by written and dated receipt of the receiving party. The mailing address, email address and
facsimile number for notice to either party will be as shown on the signature page of this Agreement. Either party may change its
mailing address, email address or facsimile number by notice as provided by this Section 9(e). 

 

    	 	4	 

     

    

 

(f)           Attorneys’
Fees. In any court action at law or equity that is brought by one of the parties to this Agreement to enforce or interpret
the provisions of this Agreement, the prevailing party will be entitled to reasonable attorneys’ fees, in addition to any
other relief to which that party may be entitled.

 

(g)           Severability.
If any provision of this Agreement is found to be illegal or unenforceable, the other provisions shall remain effective and enforceable
to the greatest extent permitted by law.

 

(h)           Amendments.
This Agreement may be amended or waived only upon written consent of the Consultant and the Company.

 

(i)           Counterparts.
This Agreement may be executed in two or more counterparts, each of which shall be deemed an original and all of which together
shall constitute one instrument.

 

[Remainder of page intentionally left
blank.]

 

    	 	5	 

     

    

 

IN WITNESS WHEREOF, the parties hereto have
executed this Consulting Agreement as of the date first written above.

 

	AmpliPhi Biosciences Corporation	 
	 	 	 
	By: 	/s/ Michael Scott Salka	 
	Name: 	Michael Scott Salka	 
	Title: 	Chief Executive Officer	 
	 	 	 
	Address:	 	 
	 	 	 
	 	 	 
	 	 	 
	Email: 	mss@ampliphibio.com	 
	 	 	 
	Consultant	 
	 	 	 
	By: 	/s/ Wendy S. Johnson	 
	 	Wendy S. Johnson	 
	 	 	 
	Address:	 	 
	 	 	 
	 	 	 
	 	 	 
	Email: 	Wendy@geminiwest.net	 

 

    	 	6	 

     

    

 

EXHIBIT A

 

SERVICES AND COMPENSATION

 

1.           Services.
Consultant shall serve as the interim Chief Operating Officer of the Company and shall perform the duties, and have the responsibilities,
that are customary for persons serving in such office. Consultant will provide the Services on an as-needed basis during the term
of the Agreement, subject to a minimum commitment of 120 hours per month (the “Minimum Services”).

 

Consultant will report to the Chief Executive
Officer of the Company.

 

2.           Compensation.

 

Monthly Fees:

 

The Company will pay Consultant a monthly
fee of $25,000 for Services performed during the term of the Agreement, subject to proration on an hourly basis in the event Consultant
does not provide the Minimum Services for any calendar month. The monthly fees will be payable in arrears, subject to Consultant
complying with Consultant's obligation to submit invoices as described below. The Company’s payment obligations for Services
performed by Consultant during the term of the Agreement will be net of any compensatory payments made by the Company to Consultant
as of the Execution Date.

 

The Company will reimburse Consultant for
reasonable travel and other business expenses incurred by Consultant in the performance of her duties, consistent with the Company’s
reimbursement policies. Consultant will provide receipts to the Company documenting such expenses.

 

Consultant agrees to provide the Company
with an invoice for fees and expenses due in respect of the Services supplied on the 1st day of each month, commencing
October 1, 2015. The Company agrees to pay each such invoice within 30 days of it being received and approved.

 

Additional Cash Payment:

 

The Company will pay Consultant the applicable
cash payment(s) specified below upon the achievement of the applicable milestone(s), in each case, subject to the Agreement remaining
in effect as of the applicable milestone achievement date:

 

	Milestone*	 	Cash
    Payment	 	 	Payment
    Timing
	Milestone
    A: Dosing, on or before December 31, 2015, of the first patient in the first clinical
    trial initiated by the Company after the Effective Date.	 	$	175,000	 	 	Within 10 days following the achievement of Milestone A.
	Milestone B:
    Dosing, after December 31, 2015 but before March 31, 2016, of the first patient in the first clinical trial initiated
    by the Company after the Effective Date.	 	$	75,000	 	 	Within 10 days following the achievement of Milestone B.
	Milestone C:
    Dosing, before March 31, 2016, of the first patient in the second clinical trial initiated by the Company after the Effective
    Date, provided such second clinical trial and/or the first clinical trial contemplated by Milestones A and B above is conducted
    under a U.S. IND.	 	$	25,000	 	 	Within 10 days following the achievement of Milestone C.

 

 

* For clarity, Milestone A and Milestone
B above will be mutually exclusive.

 

Option Grant:

 

Subject to approval by the Company’s
Board of Directors (the “Board”) or an authorized committee thereof, Consultant will be granted, under the Company’s
Stock Incentive Plan, a stock option to purchase a number of shares of common stock equal to 0.5% of the total number of outstanding
shares of common stock of the Company on the Effective Date, which option will vest as follows:

 

    	 	A-1	 

     

    

 

		·	50% of the shares subject to the option will vest on an equal monthly basis over the 12 months
following the Effective Date, subject, in each case, to the Agreement remaining in effect as of the applicable vesting date; and

 

		·	50% of the shares subject to the option will vest upon the achievement of Milestone A or Milestone
B above, subject to the Agreement remaining in effect as of the achievement of such milestone.

 

The per share exercise price of the option
will be the fair market value of the Company’s common stock on the date of grant, as determined by the Board or an authorized
committee thereof.

 

3.           Other
Engagements. Consultant may accept other consulting assignments, and engage in other business activities, so long as they do
not interfere with her obligations under this Agreement.

 

    	 	A-2	 

     

    

 

EXHIBIT B

 

LIST OF PRIOR INVENTIONS EXCLUDED UNDER
SECTION 3(C)

 

	Title	 	Date	 	
        Identifying Number

        or Brief Description

	 	 	 	 	 
	 	 	 	 	 

 

		x	No inventions or improvements

 

		 ̈	Additional Sheets Attached

 

	Signature of Consultant: 	/s/ Wendy S. Johnson	 

 

	Print Name of Consultant: 	Wendy S. JohnsonEXHIBIT 10.1

 

EMPLOYMENT AGREEMENT

 

This AGREEMENT (the
“Agreement”), dated as of May ___, 2015, is made between PlasmaTech Biopharmaceuticals, Inc., a Delaware corporation
located at 4848 Lemmon Avenue, Suite 517, Dallas, Texas 75219, (“PlasmaTech” or the “Company”),
and Timothy J. Miller, an individual residing at 2240 Delaware Drive, Cleveland Heights, OH 44106 (the “Executive”).

 

WITNESSETH:

 

WHEREAS, in connection
with that certain Agreement and Plan of Merger by and among the Company, PlasmaTech Merger Sub, Inc., Abeona Therapeutics LLC,
and Member Representative dated as of even date herewith (the “Merger Agreement”), the Company desires that
Executive serve as the Company's President and Chief Executive Officer (“CEO”);

 

WHEREAS, in order to
induce Executive to agree to serve in such capacity, the Company hereby offers Executive certain compensation and benefits of employment,
as described herein; and

 

WHEREAS, Executive
is willing to serve in this position on the terms and conditions hereinafter set forth.

 

NOW, THEREFORE, in
consideration of the premises and of the mutual covenants contained herein, the Company and Executive hereby agree as follows:

 

1.   Employment

 

The Company hereby
agrees to employ Executive and Executive hereby agrees to be employed upon the terms and conditions hereinafter set forth. During
the Term (as defined below), Executive shall serve as the President and CEO of the Company. Executive shall be responsible to the
Board of Directors of the Company, rendering the services and performing the duties consistent with Executive's position and title,
and such other reasonable duties as the Board of Directors of the Company (together with any applicable sub-committee or sub-committees
thereof, the “Board”) may request. The Executive shall also be nominated to serve as a voting member on the
Board of Directors for the Term (as defined below). If the Executive is no longer the CEO of the Company, he shall immediately
tender his resignation as a member of the Board to the Board.

 

The Executive agrees,
while employed hereunder, to perform his duties faithfully and to the best of his ability. The Executive shall be employed at the
Company's offices in Cleveland, OH, and his principal duties shall be performed primarily in Cleveland, OH, except for business
trips reasonable in number and duration.

 

    	 	 	 

     

    

 

2.   Term

 

The employment of the
Executive hereunder shall begin on the Closing Date (as such term is defined in the Merger Agreement) of the Merger Agreement (the
“Effective Date”) and shall continue in full force and effect for a period of three (3) years, and thereafter
shall be automatically renewed for successive one-year periods unless the Company gives the Executive written notice of termination
within six (6) months prior to the end of any such period or until the occurrence of a Termination Date, as defined in Section
5 (the “Term”). If the Company provides written notice of termination as described above, then the last day
of the Term will be considered the Termination Date by General Discharge (as defined in Section 5.1.6), and the Executive will
be entitled to all benefits attributable to General Discharge as defined in Section 5.2. Notwithstanding anything contained herein
to the contrary, if there is no Closing (as defined in the Merger Agreement) for any reason or the Merger Agreement is otherwise
terminated prior to the Closing Date, this Agreement shall immediately terminate and shall become null and void.

 

3.   Compensation

 

3.1.   As compensation for the Executive's
services during the Term, the Company shall pay the Executive an annual base salary at the rate of $350,000 (the “Base
Salary”), payable monthly on the last day of each month during the Term. Prior to the end of each calendar year during
the Term, the Compensation Committee of the Company shall undertake an evaluation of the services of the Executive during the calendar
year then ended in accordance with the Company's compensation program then in effect (the “Program”). The Company
shall consider the performance of the Executive, his contribution to the success of the Company and entities under common control
with the Company (collectively, “Affiliates”), and such other factors as the Compensation Committee considers
relevant in its sole discretion and shall fix an annual base salary not less than $350,000 per year to be paid to the Executive
during the ensuing calendar year.

 

3.2   Notwithstanding the foregoing, the
Company may change the Program from time to time or institute a successor to the Program, but the Executive's Base Salary shall
in no event be less than his Base Salary in effect on the date of change, adjusted regularly to reflect increases in the cost of
living and comparable compensation for like positions.

 

3.3.   The executive shall be eligible to
participate in the Company incentive compensation programs in accordance with the following subparagraphs (i) and (ii):

 

(i)   Incentive Plan - The executive shall
be covered by any cash bonus plan maintained by the Company, as in effect from time to time, and shall be afforded the opportunity
thereunder to receive a target award of up to 30% of annual Base Salary (an “Annual Bonus”) payable in cash,
as well as an allocation of options to purchase shares of PlasmaTech’s Common Stock or restricted shares of Common Stock,
as applicable, at the sole discretion of the Compensation Committee which shall make its evaluation prior to the end of each calendar
year during the Term of this Agreement. The Annual Bonus will be calculated and be paid in accordance with the terms of the Company’s
cash bonus plan, within 30 days after the end of the applicable calendar year. Such cash and equity bonus awards shall be made
by the Compensation Committee based upon, among other factors, the achievement of reasonable performance goals; provided that the
Company may from time to time change the Program or institute a successor to the Program, so long as the Executive continues to
be eligible to receive bonus awards of the percentage of annual Base Salary in amounts at least equal to those specified as in
effect on the date hereof.

 

    	 	 	 

     

    

 

(ii)   Stock Option Plan - Executive shall
be entitled to participate in the Company's stock option plan, as in effect from time to time. In accordance with this plan the
Compensation Committee may from time to time, but without any obligation to do so, grant stock options, restricted stock awards
or other equity compensation awards to the Executive upon such terms and conditions as the Compensation Committee shall determine
in its sole discretion. As soon as practicable following the Effective Date, and subject to the approval of the Compensation Committee
and the adoption and approval of the Company’s 2015 Equity Incentive Plan (the “Equity Incentive Plan”)
by Company stockholder approval, the Company shall grant, pursuant to a Company standard stock option agreement (the “Option
Agreement”) to be entered into between the Company and the Executive, a stock option (the “Option”)
to purchase 400,000 shares of the Company’s Common Stock (the “Option Shares”) at an exercise price per
share equal to the closing price of shares of Common Stock on the NASDAQ on the date of grant. The Option Shares will vest over
a forty-eight (48) month period, with one quarter (25%) of vesting on the one-year anniversary of the Effective Date and the remaining
seventy-five percent (75%) of the Option Shares vesting in equal monthly installments thereafter over the remaining thirty-six
(36) months, commencing with the first such month following the first anniversary of the Effective Date, subject to the Executive’s
continued employment with the Company and/or its Affiliates through to the applicable vesting dates, and subject to the terms and
conditions of the Company’s Equity Incentive Plan.

 

3.4   If the Executive is prevented by disability,
for a period of six consecutive months, from continuing fully to perform the essential functions of his duties as CEO, with or
without reasonable accommodations, the Employee shall perform his obligations hereunder to the extent he is able and after the
following six months (in other words, twelve months after the disability was identified by the Company as affecting his work performance)
the Company may reduce his annual Base Salary to reflect the extent of the disability; provided that in no event may such rate,
when added to payments received by him under any disability or qualified retirement or pension plan to which the Company or an
Affiliate contributes or has contributed, be less than $200,000. The Company acknowledges that it has an obligation to provide
reasonable accommodation to Executive for a disability in accordance with the Americans with Disability Act and similar state laws
and will not reduce Executive’s salary if he can perform the essential functions of his duties as CEO with or without reasonable
accommodation. If there should be a dispute about the existence of Executive's disability, or his ability to perform essential
functions of his duties as CEO, disability shall be determined by a majority vote of the Board (with the Executive abstaining from
any such vote) based upon a report from a physician, reasonably acceptable to the Executive and the Company, who shall have examined
the Executive. If the Executive claims disability, the Executive agrees to submit to a physical examination at any reasonable time
or times by a qualified physician designated by the Board and reasonably acceptable to the Executive.

 

4.   Executive Benefits

 

4.1.   During the Term, the Executive shall
be entitled to participate in the employee benefit plans and programs maintained by the Company that are made generally available
to other executive officers of the Company, including (without limitation) retirement plans, deferred compensation plans, health
and welfare plans and fringe benefit programs, subject in each case to the eligibility and other terms and conditions of the plan
or program in question, as in effect from time to time.

 

    	 	 	 

     

    

 

4.2. During the Term, the Company shall
maintain directors’ and officers’ liability insurance applicable to the Executive in amounts established by the Board
of Directors and comparable to the amounts provided for like positions.

 

4.3. The Company shall pay, or reimburse
the Executive for, all reasonable relocation expenses incurred by the Executive to be approved by the Board, relating to any relocation
if said relocation is in the best interests for the Company to conduct business. If the Executive terminates his employment pursuant
to a General Resignation (as defined below) or is terminated by the Company pursuant to a Discharge for Cause (as defined below)
during the 6 month period following the Effective Date, the Executive shall be required to repay the Company the gross amount of
any relocation expenses paid.

 

5.   Termination Date; Consequences for Compensation
and Benefits

 

5.1. Definition of Termination Date. The
first to occur of the following events shall be the “Termination Date”:

 

5.1.1. The date on which the Executive’s
employment is terminated by the Company by reason of his disability;

 

5.1.2. The Executive's death;

 

5.1.3. Voluntary resignation after one
of the following events shall have occurred, which event shall be specified to the Company by the Executive at the time of resignation:
(i) a material diminution in the Executive’s authority, duties, or responsibilities or (ii) any other action or inaction
that constitutes a material breach by the Company of this Agreement (including, without limitation, any material failure by the
Company to grant the Option for the Executive to purchase the Option Shares pursuant to the terms of Section 3.3(ii) of this Agreement),
provided that the Executive has provided written notice to the Company of the existence of any event described in (i) or (ii) above
within 60 days of the initial existence of the event and the event continues for 60 days following such notice (the “Cure
Period”) without being remedied by the Company, and provided further that such voluntary resignation occurs within 30
days after the end of the applicable Cure Period (“Resignation with Reason”);

 

5.1.4. Voluntary resignation (other than
a Resignation with Reason) not accompanied by a notice of reason described in Section 5.1.3 (“General Resignation”);

 

5.1.5 Discharge of the Executive by the
Company after one of the following events shall have occurred, which event shall be specified in writing to the Executive by the
Company at the time of discharge:

 

    	 	 	 

     

    

 

(i) a felonious act committed by Executive
during his employment hereunder or commission of any act of fraud or any other act of dishonesty of a material nature with respect
to the Company (including, but not limited to, theft or embezzlement of Company funds or assets), (ii) any act or omission on the
part of Executive not requested or approved by the Company constituting willful malfeasance or gross negligence in the performance
of his duties hereunder, (iii) conviction of the Executive or the entry of a plea of guilty or nolo contendere by the Executive
to any crime involving moral turpitude, (iv) any material breach of any material term of this Agreement by the Executive which
is not cured within 60 days after written notice from the Board to the Executive setting forth the nature of the breach (“Discharge
for Cause”);

 

For purposes of this subparagraph (5.1.5),
no act or failure to act on the Executive's part shall be considered "willful" unless done or omitted to be done by Executive
not in good faith and without reasonable belief by Executive that Executive's action or omission was in the best interest of the
Company. Notwithstanding the foregoing, Executive shall not be deemed to have been discharged for a Discharge for Cause unless
and until there shall have been delivered to Executive a copy of a Notice of Termination (as defined below) from the Board stating
that in their good faith opinion Executive was guilty of conduct set forth in clauses (i), (ii), (iii) or (iv) above of this subparagraph
(5.1.5) and specifying the particulars thereof in detail.

 

5.1.6 Discharge of the Executive by the
Company other than a Discharge for Cause or by reason of the Executive’s disability (“General Discharge”).

 

For purposes of this Agreement "Notice
of Termination" shall mean a notice which indicates the specific termination provision in this Agreement relied upon and sets
forth in reasonable detail the facts and circumstances claimed to provide a basis for termination of Executive's employment under
the provision so indicated. Except for Discharge for Cause, each Notice of Termination shall be delivered at least ten (10) days
prior to the effective date of termination.

 

5.2 Consequences for Compensation and Benefits

 

(a) If the Termination Date occurs by reason
of disability, death, General Resignation or Discharge for Cause, the Company shall pay or provide, as the case may be, (i) any
Base Salary earned but unpaid to the Executive through the Termination Date, (ii) all benefits accrued and owing to the Executive
through the Termination Date, payable in accordance with the respective terms of the plans, practices and arrangements under which
the benefits were accrued, and (iii) any unpaid reimbursements for reasonable expenses incurred but not paid prior to the Termination
Date so long as documentation thereof is submitted to the Company within thirty (30) days following the Termination Date.

 

    	 	 	 

     

    

 

(b) If the Termination Date occurs by reason
of General Discharge or Resignation with Reason, (i) all unvested Option Shares held by the Executive pursuant to the Option shall
immediately vest and become immediately exercisable for the period set forth in the Option Agreement and the Equity Incentive Plan,
(ii) if the Executive elects coverage under Section 4980B of the Internal Revenue Code of 1986, as amended (the “Code”),
or under similar applicable health care continuation coverage laws of a State (“COBRA”), the Company shall reimburse
the Executive for that portion of the cost of the continuation coverage that the Company pays for similarly situated active employees
of the Company, for Executive and Executive’s covered dependents (but not for any spouse or dependent who separately elects
COBRA coverage as a “qualified beneficiary,” as defined in Code Section 4980B(g)(1)), for a period ending upon the
earlier of twelve (12) months after the Termination Date or the date the Executive’s COBRA coverage ceases (the “Health
Severance”), provided, however, that the Health Severance shall be payable only to the extent that it would not
result in a tax or penalty to the Company under the Patient Protection and Affordable Care Act of 2010, as amended, and regulations
thereunder (“ACA”), and further provided that the Company may elect, in its sole discretion, to report
the Health Severance as taxable income to the Executive in order to satisfy the requirements of Section 105(h) of the Code or Section
2716 (Prohibition on Discrimination in Favor of Highly Compensated Individuals) of the Public Health Service Act, as incorporated
by Section 9815(a)(1) of the Code, (iii) the Executive shall be entitled to receive the amount set forth in Section 5.2.1, which
shall be paid on or before the 60th day following the Termination Date, provided that the Executive signs a valid and effective
Release (defined in Section 5.2.3) in the time set forth in such Release (which shall in no case cause the payment under this Section
5.2(b)(iii) to be made after the 60 day period after the Termination Date), and provided that, if such 60-day period straddles
two taxable years, the payment shall be made in the second taxable year, and (iv) the Company shall reimburse Executive for any
unpaid reimbursements for reasonable expenses incurred but not paid prior to the Termination Date so long as documentation thereof
is submitted to the Company within ten (10) days following the Termination Date.

 

5.2.1. A lump sum payment equal to one
times (1x) the Executive’s Base Salary for the year in which the Termination Date occurs.

 

5.2.2 . If the Executive's
employment is terminated by the Executive pursuant to a General Resignation, the Executive shall be entitled to receive any earned
but unpaid Annual Bonus with respect to any completed calendar year immediately preceding the Termination Date, which shall be
paid on the otherwise applicable payment date except to the extent payment is otherwise deferred pursuant to any applicable deferred
compensation arrangement.

 

5.2.3. The severance
payments and benefits described in this Section 5 are expressly contingent on the Executive’s execution of a severance and
release agreement (a “Release”) in substantially the form attached hereto as Exhibit A within the time
set forth in the Release, and such Release becoming effective by its terms on or before the 60th day following the Termination
Date.

 

5.3 Change in Control. In the event of
the occurrence of a Change in Control (as defined below), this Agreement may be terminated by Executive upon the occurrence thereafter
of one or more of the following events:

 

1) A material diminution in Executive’s
authority, duties, or responsibilities within the six month period subsequent to a Change in Control;

 

2) A material diminution in Executive’s
compensation within the six month period subsequent to a Change in Control, which shall include the occurrence of any of the following
without the prior written consent of Executive: (i) a material reduction in the aggregate of Executive’s then-current Base
Salary or a material reduction in the benefits under, or becoming ineligible to participate in, the Company incentive compensation
programs outlined in Section 3.3 of this Agreement, or (ii) a material reduction in the scope or value of the Executive’s
overall compensation and benefits;

 

    	 	 	 

     

    

 

3) A breach of Section 11.5 of this Agreement
by either the Company or any successor or successors to which all or a significant portion of its business and/or assets have been
transferred (directly or by operation of law), which the parties hereby agree and acknowledge constitutes a material breach of
this Agreement;

 

4) A General Discharge of Executive within
the six month period subsequent to a Change in Control; or

 

5) A breach of the requirement under Section
1 of this Agreement that Executive shall be nominated to serve as a voting member on the Board for the duration of the Term, which
the parties hereby agree and acknowledge constitutes a material breach of this Agreement;

 

provided that the Executive has provided
written notice to the Company (or any successor, as the case may be) of the existence of any event described in 1) through 5) above
with 30 days of the initial existence of the event and the event continues for 30 days following such notice (the “Change
in Control Cure Period”) without being remedied by the Company (or any successor, as the case may be), and provided further
that such termination of this Agreement occurs within 60 days after the end of the applicable Change in Control Cure Period.

 

5.3.1 A “Change in Control”
of the Company as used in this Agreement shall be deemed to have occurred upon the first to occur of the date when (a) a person
or group "beneficially owns" (as defined in Rule 13d-3 promulgated under the Securities Exchange Act of 1934) in the
aggregate 50% or more of the outstanding shares of capital stock entitled to vote generally in the election of the Directors of
the Company or (b) there occurs a sale of all or substantially all of the business and/or assets of the Company, all other than
to an affiliate of the Company or through a reorganization or similar restructuring of the Company; provided, that a Change in
Control shall not be deemed to occur if any current shareholder of the Company becomes a beneficial owner of 50% or more of the
outstanding shares of the Company.

 

5.3.2 If a Change in Control of the Company
shall have occurred within six (6) months prior to the Termination Date (other than a Termination Date due to a General Resignation,
a termination due to the Executive’s disability, or a Discharge for Cause) or the Executive terminates this Agreement under
Section 5.3, then, following such Termination Date, (i) the Executive will be entitled to receive a lump sum payment equal to two
(2) times the sum of the Executive's Base Salary for the year in which the Termination Date occurs, which shall be paid on the
60th day following the Termination Date, provided that the Executive signs a valid and effective Release in the time set forth
in such Release (which shall in no case cause the payment under this Section 5.3.2(i) to be made after the 60 day period after
the Termination Date), (ii) all unvested Option Shares held by the Executive shall immediately vest and become immediately exercisable
and shall remain exercisable in accordance with the terms thereof and the Company’s Equity Incentive Plan , and (iii) the
Executive shall be entitled to Health Severance, upon the terms set forth in Section 5.2(b(ii), for a period ending upon the earlier
of six (6) months after the Termination Date or the date the Executive’s COBRA coverage ceases.

 

    	 	 	 

     

    

 

6.   Indemnification

 

In the event that the
Executive is made a party or threatened to be made a party to any action, suit, or proceeding, whether civil, criminal, administrative
or investigative (a “Proceeding”), other than any Proceeding initiated
by the Executive or the Company related to any contest or dispute between the Executive and the Company or any of its affiliates
with respect to this Agreement or the Executive's employment hereunder, by reason of the fact that the Executive is or was a director
or officer of the Company, or any affiliate of the Company, or is or was serving at the request of the Company as a director, officer,
member, employee or agent of another corporation or a partnership, joint venture, trust or other enterprise, the Executive shall
be indemnified and held harmless by the Company to the maximum extent permitted under applicable law from and against any liabilities,
costs, claims and expenses, including all costs and expenses incurred in defense of any Proceeding (including attorneys' fees).
Costs and expenses incurred by the Executive in defense of such Proceeding (including attorneys' fees) shall be paid by the Company
in advance of the final disposition of such litigation upon receipt by the Company of: (i) a written request for payment; (ii)
appropriate documentation evidencing the incurrence, amount and nature of the costs and expenses for which payment is being sought;
and (iii) an undertaking adequate under applicable law made by or on behalf of the Executive to repay the amounts so paid if it
shall ultimately be determined that the Executive is not entitled to be indemnified by the Company under this Agreement.

 

7.   Fulfillment of Duties

 

During the Term, The Executive shall devote
substantially all of his business time and attention, skills and best efforts to the performance of his duties herein for the Company,
its Subsidiaries and Affiliates and shall not, during the Term, engage in any other business, profession or occupation for compensation
or otherwise which would conflict with, compete with or otherwise interfere with the performance of such services with directly
or indirectly without the prior written consent of the Board. Notwithstanding the foregoing, nothing contained herein shall preclude
the Executive from (a) serving on the boards of directors of other companies or organizations with the approval of the Board (not
to be unreasonably withheld) or serving on the boards of directors of not-for-profit companies or organizations without the approval
of the Board, (b) investing in and managing passive investments, or (c) pursuing his personal, financial and legal affairs provided
that such activity does not materially interfere with the performance of the Executive's obligations hereunder. The Executive’s
activities and roles within Red5 Pharmaceuticals shall not be a violation of this Agreement.

 

8.   Agreement Not to Compete, Not to Solicit

 

The Executive agrees that the following
obligations are reasonable and are necessary to protect the Company’s goodwill and business interests, these obligations
do not restrict the Executive’s ability to be gainfully employed, and the Executive acknowledges that any geographic boundary,
scope of prohibited activities, and time duration in these obligations are reasonable in nature and no broader than are necessary
to protect the Company’s legitimate goodwill and business interests.

 

    	 	 	 

     

    

 

For one year following any Termination
Date, regardless of the reason, the Executive agrees not to, singly, jointly or as a partner, member, employee, agent, officer,
consultant, independent contractor, officer, director, stockholder (except as a holder, for investment purposes of not more than
three percent (3%) of the outstanding stock of any company listed on a national securities exchange, or actively traded in a national
over-the-counter market), equity holder, lender, or joint venturer of any other person, or in any other capacity, directly or beneficially,
own, manage, operate, join, control, participate in the ownership, management, operation or control of, or permit the use of his
name by, or work for, or provide consulting, financial or other assistance to any person engaged in, or otherwise engage in (other
than on behalf of the Company) the business of developing pharmaceutical products or platform technologies that are similar or
substantially similar to those of the Company (the “Business”) as of the Termination Date in any state in which
the Company conducts the Business as of the Termination Date.

 

For one year following any Termination
Date, regardless of the reason, the Executive shall not solicit any employee of the Company or an Affiliate to leave such employment
and to provide services to the Executive or any business entity by which the Executive is employed or in which the Executive has
a material financial interest. Soliciting a former employee of the Company and its Affiliates to provide such services shall not
be a violation of this Agreement.

 

9.   Confidential Information

 

The Executive acknowledges that during
his employment with the Company, he will have access to trade secrets and other non-public confidential and/or proprietary information
relating to the Company’s business (“Confidential Information”), which will be the exclusive property
of the Company. The following does not constitute “Confidential Information”: information (i) which is, at the time
Executive receives such information, available to the general public; (ii) which becomes at a later date available to the general
public through no fault of the Executive and then only after said later date; or (iii) which the Executive can demonstrate by written
record was in his possession prior to the Term. Unless the Executive shall first secure the written consent of the Company or unless
required pursuant to a legal proceeding, the Executive shall not disclose or use, either during or after the Term for a period
of five (5) years, any Confidential Information of the Company or any Affiliate, whether or not developed by the Executive, except
as required by his duties to the Company or the Affiliate or under applicable law.

 

Concurrently with the execution of this
Agreement, the Executive will sign a standard Confidential Disclosure and Limited Use Agreement, which shall control over this
Agreement if any conflict exists between it and this Agreement.

 

10.   Arbitration

 

Any dispute or differences concerning any
provision of this Agreement which cannot be settled by mutual accord between the parties shall be settled by arbitration in New
York, New York, in accordance with the rules then in effect of the American Arbitration Association, except as otherwise provided
herein. The dispute or differences shall be referred to a single arbitrator, if the parties agree upon one, or otherwise to three
arbitrators, one to be appointed by each party and a third arbitrator to be appointed by the first named arbitrators; and if either
party shall refuse or neglect to appoint an arbitrator within 30 days after the other party shall have appointed an arbitrator
and shall have served a written notice upon the first mentioned party requiring such party to make such appointment, then the arbitrator
first appointed shall, at the request of the party appointing him, proceed to hear and determine the matters in difference as if
he were a single arbitrator appointed by both parties for the purpose, and the award or determination which shall be made by the
arbitrator shall be final and binding upon the parties hereto.

 

    	 	 	 

     

    

 

The arbitrator or arbitrators shall each
have not less than five-(5) years’ experience in dealing with the subject matter of the dispute or differences to be arbitrated.
Any award may be enforced in any court of competent jurisdiction. The expenses of any such arbitration shall be paid by the non-prevailing
party, as determined by the final order of the arbitrators.

 

The non-prevailing party in any dispute
agrees to pay all reasonable legal fees and expenses of the prevailing party in connection with any dispute under this Agreement.

 

11.   Miscellaneous

 

11.1 Notices

 

All notices in connection with this Agreement
shall be in writing and sent by postage prepaid first class mail, courier, or telefax, and if relating to default or termination,
by certified mail, return receipt requested, addressed to each party at the address indicated below:

 

If to the Company:

PlasmaTech Biopharmaceuticals, Inc.

4848 Lemmon Avenue

Suite 517

Dallas, TX 75219

Attn: Chief Financial Officer

 

Copy To:

John J. Concannon III, Esq.

Morgan Lewis & Bockius LLP

One Federal Street

Boston, MA 02110

 

If to the Executive:

Timothy J. Miller

2240 Delaware Drive

Cleveland, OH 44106

 

Or to such other address as the addressee
shall last have designated by notice to the communicating party. The date of giving of any notice shall be the date of actual receipt.

 

11.2 Governing Law

 

This Agreement shall be governed by the
internal and substantive laws of the State of Delaware.

 

    	 	 	 

     

    

 

11.3 Severability

 

Whenever possible, each provision of this
Agreement shall be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Agreement
is held to be invalid, illegal or unenforceable in any respect under any applicable law or rule in any jurisdiction, such invalidity,
illegality or unenforceability shall not affect any other provision or in the interpretation in any other jurisdiction; however,
such provision shall be deemed amended to conform to applicable laws and to accomplish the intentions of the parties.

 

11.4 Entire Agreement; Amendment

 

This Agreement constitutes the entire agreement
of the parties and may be altered or amended or any provision hereof waived only by an agreement in writing signed by the party
against whom enforcement of any alteration, amendment, or waiver is sought. No waiver by a party of any breach of this Agreement
shall be considered as a waiver of any subsequent breach.

 

11.5 Successors and Assigns

 

11.5.1 Any successor of the Company (whether
direct or indirect, by purchase, merger, consolidation or otherwise) shall expressly assume and agree to perform this Agreement
in the same manner and to the same extent that the Company would be required to perform it if no such succession had taken place.
As used in this Section 11.5.1, "Company" shall mean the Company as hereinbefore defined and any successor to its business
and/or assets as aforesaid which executes and delivers the Agreement provided for in this Section 11.5.1 or which otherwise becomes
bound by all the terms and provisions of this Agreement by operation of law.

 

11.5.2 This Agreement is intended to bind
and inure to the benefit of and be enforceable by Executive and the Company, and their respective successors and assigns, except
that Executive may not assign any of his rights or delegate any of his duties without the prior written consent of the Company.

 

11.6 Assignability

 

Neither this Agreement nor any benefits
payable to the Executive hereunder shall be assigned, pledged, anticipated, or otherwise alienated by the Executive, or subject
to attachment or other legal process by any creditor of the Executive, and notwithstanding any attempted assignment, pledge, anticipation,
alienation, attachment, or other legal process, any benefit payable to the Executive hereunder shall be paid only to the Executive
or his estate.

 

11.7 Code Section 409A

 

11.7.1   To the extent applicable,
it is intended that this Agreement (including all amendments hereto) either meet the requirements for exclusion from coverage under
Code Section 409A, or alternatively comply with the requirements of Code Section 409A, so that the income inclusion provisions
of Code Section 409A(a)(1) do not apply to Executive. This Agreement shall be interpreted and administered in a manner consistent
with this intent. However, the Company does not warrant to Executive that all amounts paid or delivered to him hereunder will be
exempt from, or paid in compliance with, Code Section 409A. Executive understands and agrees that he bears the entire risk of any
adverse federal, state or local tax consequences and penalty taxes which may result from payment on a basis contrary to the provisions
of Code Section 409A or comparable provisions of any applicable state or local income tax laws. Executive acknowledges that he
has been advised to seek the advice of a tax advisor with respect to the tax consequences of all payments pursuant to this Agreement,
including any adverse tax consequence under Code Section 409A and applicable state tax law.

 

    	 	 	 

     

    

 

11.7.2 To the extent that payment of amounts
under this Agreement that are subject to Code Section 409A are payable upon Executive’s termination of employment, such amounts
shall only be payable if such termination also constitutes a “separation from service,” within the meaning of Code
Section 409A, from the Company. If the Executive is deemed on the date of his separation from service to be a “specified
employee” within the meaning of Code Section 409A(a)(2)(B), of the Company, then, notwithstanding any other provision herein,
with regard to any payment that is nonqualified deferred compensation subject to Code Section 409A and that is payable on account
of Executive’s “separation from service,” such payment shall not be made prior to the earlier of (i) the expiration
of six months following the date of Executive’s separation from service, and (ii) the date of the Executive’s death,
following which all payments so delayed shall be paid to the Executive in a lump sum without interest.

 

11.7.3 Any taxable reimbursement of business
or other expenses provided for under this Agreement that is subject to Code Section 409A shall be subject to the following conditions:
(i) the expenses eligible for reimbursement in one taxable year shall not affect the expenses eligible for reimbursement in any
other taxable year; (ii) the reimbursement of an eligible expense shall be made no later than the end of the year after the year
in which such expense was incurred; and (iii) the right to reimbursement shall not be subject to liquidation or exchange for another
benefit.

 

11.7.4 In applying Code Section 409A to
amounts paid pursuant to this Agreement, any right to a series of installment payments under this Agreement shall be treated as
a right to a series of separate payments. Whenever a payment under this Agreement specifies a payment period within a specified
number of days, the actual date of payment within the specified period shall be within the sole discretion of the Company.

 

[Remainder of Page Intentionally Left
Blank]

 

    	 	 	 

     

    

 

IN WITNESSES WHEREOF, the Company and its
officers hereunto duly authorized, and the Employee have signed and sealed this Agreement as of the date first written above.

 

PLASMATECH BIOPHARMACEUTICALS, INC.

 

	By:	/s/ Steven H. Rouhandeh	 
	 	     Name:  Steven H. Rouhandeh	 
	 	     Title:  Chairman	 
	 	 
	EXECUTIVE:	 
	 	 
	/s/ Timothy J. Miller	 
	Timothy J. Miller

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00251-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00251-of-00352.parquet"}]]